Led · Equity · Jul 2024

Radical Catheter Technologies designs and commercializes a novel endovascular access and delivery platform built on a patented ribbon technology. Its first product, the 7F Radical Catheter, received U.S. FDA 510(k) clearance and is cleared for neurovascular femoral and radial access. A multi-center retrospective analysis of 85 neuroendovascular procedures reported 100% catheterization of target vessels, intracranial reach in all anterior circulation treatments, no device failures or device-related adverse events, and elimination of intermediate catheters in most applicable cases. The company highlights benefits including greater flexibility, stability, durability, reduced procedural time, and potential cost and risk reductions. Co-founders Brian Martin and Martin Dieck have worked on neurosurgical technologies for three decades. Radical plans to scale operations, build a world-class manufacturing organization, expand the Radical platform, and leverage post-clearance clinical data as it commercializes the technology.

Participated · Series C · Dec 2022

Synchron is a New York City–based neurotechnology company building the Stentrode platform, an endovascular brain-computer interface (BCI) that is delivered via catheter rather than open-brain surgery. Once implanted, the device interfaces with the motor cortex through the blood vessels and wirelessly transmits neural signals that can be translated into hands-free digital commands. Ten patients with paralysis have received the Stentrode across U.S. and Australian clinical trials, demonstrating early clinical adoption. Led by founder and CEO Tom Oxley, the company plans to use newly raised capital to scale operations and advance product development. Synchron’s ultimate goal is to commercialize a clinically viable, minimally invasive BCI for widespread medical use. Including the latest round, the company has secured $345 million in total funding to date, underlining strong investor confidence in its technology and market potential.